What it is
MK-677, also known as Ibutamoren or Nutrobal, is an oral growth hormone secretagogue that mimics the action of ghrelin, the hunger hormone. Developed by Reverse Pharmacology and later licensed to Merck, it increases growth hormone and insulin-like growth factor 1 (IGF-1) levels without requiring injections.
Unlike traditional growth hormone injections or peptide injections like Ipamorelin, MK-677 is orally bioavailable, making it convenient for daily use. It activates the ghrelin receptor in the pituitary gland, triggering natural growth hormone release in a pulsatile manner that resembles natural physiology.
Originally investigated for treating growth hormone deficiency and muscle wasting in elderly populations, MK-677 has gained attention for its potential benefits in body composition, sleep quality, and recovery. While not FDA-approved for any indication, it remains available as a research chemical and is widely used in fitness and anti-aging communities.
How it works
MK-677 functions as a ghrelin receptor agonist, binding to the same receptors that the natural hunger hormone ghrelin activates. When MK-677 binds to these receptors in the pituitary gland, it stimulates the release of growth hormone-releasing hormone (GHRH), which in turn triggers growth hormone secretion from the anterior pituitary.
This increased growth hormone release leads to elevated IGF-1 levels in the liver and other tissues. IGF-1 is responsible for many of the anabolic effects associated with growth hormone, including increased protein synthesis, enhanced muscle growth, improved bone density, and accelerated tissue repair.
The compound maintains natural growth hormone pulsatility patterns, unlike continuous growth hormone injections. This pulsatile release may reduce the risk of receptor desensitization and maintain more physiological hormone patterns. The 24-hour half-life allows for once-daily dosing while providing sustained growth hormone elevation throughout the day.
MK-677 also increases appetite through its ghrelin-like activity, which can be beneficial for those trying to gain muscle mass but problematic for those focused on fat loss. The compound may also improve sleep quality by enhancing REM sleep duration, though the exact mechanism for this effect remains unclear.
What the research shows
Clinical studies demonstrate MK-677's ability to significantly increase growth hormone and IGF-1 levels. In a phase 2 trial involving 65 healthy young men, 25mg of MK-677 daily for 8 weeks increased IGF-1 levels by 89% and growth hormone levels by 79% compared to placebo. These elevations persisted throughout the treatment period without tachyphylaxis (Copinschi et al., Journal of Clinical Endocrinology & Metabolism, 1996. PMID: 8964758).
Long-term safety and efficacy data comes from studies in elderly populations. A randomized controlled trial of 292 elderly adults found that MK-677 25mg daily for 2 years increased lean body mass by 1.1 kg and improved sleep quality scores. However, the study also noted increases in fasting glucose and HbA1c levels, raising concerns about glucose metabolism (Nass et al., Journal of Clinical Endocrinology & Metabolism, 2008. PMID: 18349056).
Studies in growth hormone-deficient adults show meaningful clinical benefits. A 6-month trial of 24 adults with severe growth hormone deficiency found that MK-677 25mg daily increased IGF-1 to normal ranges and improved nitrogen balance, suggesting enhanced protein synthesis. Sleep quality improvements were noted within 2 weeks of treatment (Chapman et al., Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9329386).
Research on bone density and fracture healing shows mixed results. While some studies demonstrate improved bone turnover markers, clinical trials have not consistently shown significant improvements in bone density after 1-2 years of treatment. The effects appear more pronounced in younger subjects and those with existing growth hormone deficiency (Murphy et al., European Journal of Endocrinology, 1998. PMID: 9973218).
Typical protocol
MK-677 dosing typically ranges from 10-25mg daily, taken orally with or without food. Most users start with 10mg daily for the first week to assess tolerance, particularly regarding appetite increase and potential lethargy. The dose can be gradually increased to 15mg and then 25mg based on individual response and side effect tolerance.
Timing recommendations vary based on individual response to the compound's effects. Many users prefer taking MK-677 before bed due to its sleep-enhancing properties and to minimize daytime lethargy. However, some users experience vivid dreams or restless sleep and prefer morning dosing. The long half-life means timing is less critical than consistency.
Cycle length protocols differ based on goals and tolerance. Conservative approaches suggest 8-12 week cycles followed by 4-8 week breaks to prevent potential glucose metabolism issues and allow natural hormone recovery. More aggressive users run longer cycles of 6-12 months, particularly when using MK-677 for legitimate growth hormone deficiency under medical supervision.
Blood work monitoring is recommended every 3-4 months during use, focusing on fasting glucose, HbA1c, IGF-1 levels, and prolactin. Some users combine MK-677 with berberine or metformin to mitigate potential glucose elevation. The compound requires no special preparation and can be taken as a simple oral capsule or liquid solution. Use our calculator if you need to convert dosing from powder form.
Side effects and risks
The most common side effect of MK-677 is significantly increased appetite, occurring in nearly all users within days of starting treatment. This can be beneficial for those trying to gain muscle mass but problematic for those in a caloric deficit. The appetite stimulation is dose-dependent and typically peaks 2-4 hours after dosing.
Water retention and edema affect approximately 40-60% of users, particularly at higher doses. This manifests as facial bloating, swollen hands and feet, and temporary weight gain. The retention is typically mild and reversible but can be uncomfortable. Reducing sodium intake and ensuring adequate potassium may help minimize this effect.
Glucose metabolism disruption represents the most significant long-term concern. Studies show MK-677 can increase fasting glucose by 10-20% and HbA1c levels over time. Individuals with prediabetes or metabolic syndrome may be at higher risk for developing type 2 diabetes. Regular blood glucose monitoring is essential, especially during extended use.
Other reported side effects include lethargy and fatigue, particularly in the first few weeks of use, potential prolactin elevation leading to gynecomastia in sensitive individuals, and rarely, carpal tunnel syndrome with prolonged use. MK-677 is contraindicated in individuals with active cancer due to potential growth-promoting effects. Diabetics should use extreme caution and close medical supervision. Pregnancy and breastfeeding are contraindications due to unknown effects on fetal development.
Related compounds
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide protocol.